Señales en vivo de APLM | Maximiza tus Ganancias con Getagraph.com

COMPRAR 130616 min ago

@ $0.675

Emitido: 9 feb 2024 @ 09:59

Retorno: -41.20%

Señal anterior: feb 7 - 09:54

Señal anterior: Vender

Retorno: 4.44 %

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia...

Stats
Volumen de hoy	153 431
Volumen promedio	176 446
Capitalización de mercado	35.49M
EPS	$0 ( 2024-04-26 )
Próxima fecha de ganancias	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.170
ATR14	$0.00200 (0.50%)

Volumen Correlación

Largo: -0.18 (neutral)

Corto: 0.73 (moderate)

Signal:(52.354) Neutral

Apollomics, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Apollomics, Inc. Correlación - Moneda/Commodity

0.48
( neutral )

0.55
( weak )

0.00
( neutral )

-0.23
( neutral )

Apollomics, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-2.77

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-2.77

Financial Reports:

No articles found.

Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.